HER2 標的治療と心臓毒性:大きな懸念から管理可能なリスクへ
Rio Putra Pamungkas1, Laras Pratiwi1, Henry Sutanto1
1Internal Medicine Study Program, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA; Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya, INDONESIA.
Current problems in cardiology
|September 5, 2025
まとめ
HER2を標的とする治療は乳がんのアウトカムを改善しますが,心臓毒性を引き起こす可能性があります. しかし,ほとんどの心臓発作は軽度で,モニタリングで回復し,HER2治療を安全に継続することができます.
科学分野:
- 心臓腫瘍学
- 医療腫瘍学
- 心血管医学
背景:
- HER2を標的とする治療は HER2陽性乳がん治療に革命をもたらしました
- 心臓毒性は,歴史的にアントラサイクリンとHER2阻害剤と関連している重要な懸念事項です.
- 心臓毒性に関する初期の懸念のために,集中的な心臓モニタリングが開発されました.
研究 の 目的:
- HER2治療による心臓毒性の病理生理学を批判的に検討する.
- 心臓毒性に対する臨床的危険因子と管理戦略の見直し
- 監視と多科目のケアによるHER2治療の安全な継続を主張する.
主な方法:
- HER2 治療の心臓毒性に関する初期試験データと新興証拠のレビュー
- 心臓機能障害の臨床的決定因子と潜在的なバイオマーカーの分析
- 心筋細胞機能に対する HER2 阻害のメカニズム的経路の検討
- SAFE-HEaRtのような安全な治療継続に関する研究の結果を含める.
主要な成果:
- ほとんどの心臓毒性イベントは無症状で,逆行性であり,治療の中止はめったに必要ありません.
- 臨床的決定因子には,ベースラインの心臓機能,年齢,併発症,および化学療法の組み合わせが含まれます.
- バイオマーカーと高度なイメージングは 心臓病の早期発見に 有望です
- HER2 治療は,心臓腫瘍学的監視と心臓保護で安全に行うことがよくあります.
結論:
- HER2を標的とする治療による心臓毒性は,しばしば管理可能であり,逆転可能である.
- リスクの階層化,監視,統合されたケアが 最適な結果を得るために不可欠です.
- 適切なモニタリングと多学科的な管理で,心臓毒性はHER2標的がんの効果的な治療を妨げる必要はありません.
関連する概念動画
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Cardiomyopathy III: Hypertrophic Cardiomyopathy
45
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
45
Cardiomyopathy V: Interprofessional Care
30
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
30
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Cardiomyopathy VI: Nursing Management
30
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
30
Heart Failure Drugs: Inotropic Agents
716
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
716


